SCHEMBL21035405

SCHEMBL21035405

COC(=O)[C@@H]1C[C@@H](Oc2ccc(Cl)c(Oc3ccccc3)c2)CN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 4/20 0.42
MMP1 P03956 5/20 0.41
MMP3 P08254 5/20 0.41
MMP7 P09237 4/20 0.41
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MMP2 P08253 1/20 0.39
HCRTR1 O43613 5/20 0.38
HCRTR2 O43614 5/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
KAT6A Q92794 1/20 0.36
ADAM17 P78536 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21036273 1.00 MMP9 (0.42) MMP9MMP1MMP3MMP7PDE4A
SCHEMBL21036271 0.92 MMP9 (0.42) MMP9MMP1MMP3MMP7PDE4A
SCHEMBL21035522 0.90 MMP1 (0.43) MMP9MMP1MMP3MMP7PDE4A
SCHEMBL21035654 0.86 HCRTR1 (0.41) MMP9MMP1MMP3MMP7MMP2
SCHEMBL21034982 0.86 HCRTR1 (0.41) MMP9MMP1MMP3MMP7MMP2
SCHEMBL21034977 0.86 CA12 (0.46) MMP9MMP1MMP3MMP7MMP2
SCHEMBL21035352 0.86 CA12 (0.46) MMP9MMP1MMP3MMP7MMP2
SCHEMBL21035398 0.86 HTR1A (0.42) MMP9MMP1MMP3PDE4BHCRTR1
SCHEMBL21035317 0.86 HTR1A (0.42) MMP9MMP1MMP3PDE4BHCRTR1
SCHEMBL21035318 0.84 MMP1 (0.43) MMP9MMP1MMP3MMP7MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed